VivoSeq
Other

Hematopoietic Cell Transplant

0

Pipeline Programs↗

5

Active Trials↗

2

Companies Involved↗

Hematopoietic Cell Transplant is an early-stage landscape with 0 programs across 2 companies. The most active players are Astellas, CSL Behring.

Intelligence

Pipeline Metrics

Competitive Density

19/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

60/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Astellas logo

Astellas

0 programs

PreclinicalCSL Behring logo

CSL Behring

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

10

clinical trials

Recruiting4 · 40%
Completed3 · 30%
Withdrawn1 · 10%
Terminated1 · 10%
Active, not recruiting1 · 10%

Clinical Trials

Trial Activity

10 trials

Enhanced Molecular Microbiological Surveillance Versus Ceftriaxone Prophylaxis in Hematopoietic Cell Transplant Patients
Recruiting·PPomeranian Medical University Szczecin·N/A·NCT07308457·100 enrolled
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
Recruiting·—·Phase 1·NCT06543381·15 enrolled
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
Recruiting·—·Phase 1·NCT06498973·43 enrolled
Phase I/II Trial: Engineered Donor Graft (Orca Q) for Pediatric Hematopoietic Cell Transplant (HCT)
Recruiting·UUniversity of Florida·Phase 1/2·NCT05322850·40 enrolled
The Safety and Efficacy of Alpha-1 Antitrypsin (AAT) for the Prevention of Graft-versus-host Disease (GVHD) in Patients Receiving Hematopoietic Cell Transplant
Active, not recruiting·CSL Behring logoCSL Behring·Phase 2/3·NCT03805789·222 enrolled
Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies
Completed·MM.D. Anderson Cancer Center·Phase 1·NCT00410982·145 enrolled
A Study to Evaluate a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Completed·Astellas logoAstellas·Phase 3·NCT01877655·514 enrolled
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
Completed·FFred Hutchinson Cancer Center·Phase 1/2·NCT00068718·35 enrolled
Preservation of Ovarian Function After Hematopoietic Cell Transplant
Terminated·MMasonic Cancer Center, University of Minnesota·Phase 2·NCT01343368·19 enrolled
Validating Ultrasound Biomarkers for Hepatic Sinusoidal Obstruction Syndrome in Pediatric Hematopoietic Cell Transplant Patients
Withdrawn·—·Phase 4·NCT03963999

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)